Kiniksa Pharmaceuticals International, plc Cost of Revenue
Kiniksa Pharmaceuticals International, plc (KNSA) reported Cost of Revenue of $20.80 million for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-04-28.
Financial Statements › Expense Statement
us-gaap:CostOfGoodsAndServicesSold · last filed 2026-04-28
- Kiniksa Pharmaceuticals International, plc cost of goods and services sold for the quarter ending 2026-03-31 was $20.80M, a 16.39% increase year-over-year.
- Kiniksa Pharmaceuticals International, plc cost of goods and services sold for the quarter ending 2025-12-31 was $20.95M, a 17.04% increase year-over-year.
- Kiniksa Pharmaceuticals International, plc cost of goods and services sold for the quarter ending 2025-09-30 was $20.26M, a 0.74% increase year-over-year.
- Kiniksa Pharmaceuticals International, plc cost of goods and services sold for the quarter ending 2025-06-30 was $18.60M, a 50.97% increase year-over-year.
- Kiniksa Pharmaceuticals International, plc cost of goods and services sold for fiscal 2025 was $77.67M, a 27.52% increase from fiscal 2024.
- Kiniksa Pharmaceuticals International, plc cost of goods and services sold for fiscal 2024 was $60.91M, a 82.33% increase from fiscal 2023.
- Kiniksa Pharmaceuticals International, plc cost of goods and services sold for fiscal 2023 was $33.41M, a 45.91% increase from fiscal 2022.
- Kiniksa Pharmaceuticals International, plc cost of goods and services sold for fiscal 2022 was $22.89M, a 151.59% increase from fiscal 2021.
| Period end | Cost of Goods and Services Sold 3 month | Cost of Goods and Services Sold 6 month | Cost of Goods and Services Sold 9 month | Cost of Goods and Services Sold 12 month |
|---|---|---|---|---|
| 2026-03-31 | $20.80M 10-Q · filed 2026-04-28 | $41.74M derived: sum of 2 quarters · filed 2026-04-28 | $62.00M derived: sum of 3 quarters · filed 2026-04-28 | $80.60M derived: sum of 4 quarters · filed 2026-04-28 |
| 2025-12-31 | $20.95M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $41.20M derived: sum of 2 quarters · filed 2026-02-24 | $59.80M derived: sum of 3 quarters · filed 2026-02-24 | $77.67M 10-K · filed 2026-02-24 |
| 2025-09-30 | $20.26M 10-Q · filed 2025-10-28 | $38.86M derived: sum of 2 quarters · filed 2025-10-28 | $56.73M 10-Q · filed 2025-10-28 | $74.62M derived: sum of 4 quarters · filed 2026-04-28 |
| 2025-06-30 | $18.60M 10-Q · filed 2025-07-29 | $36.47M 10-Q · filed 2025-07-29 | $54.37M derived: sum of 3 quarters · filed 2026-04-28 | $74.48M derived: sum of 4 quarters · filed 2026-04-28 |
| 2025-03-31 | $17.87M 10-Q · filed 2026-04-28 | $35.76M derived: sum of 2 quarters · filed 2026-04-28 | $55.87M derived: sum of 3 quarters · filed 2026-04-28 | $68.19M derived: sum of 4 quarters · filed 2026-04-28 |
| 2024-12-31 | $17.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $38.01M derived: sum of 2 quarters · filed 2026-02-24 | $50.33M derived: sum of 3 quarters · filed 2026-02-24 | $60.91M 10-K · filed 2026-02-24 |
| 2024-09-30 | $20.11M 10-Q · filed 2025-10-28 | $32.43M derived: sum of 2 quarters · filed 2025-10-28 | $43.01M 10-Q · filed 2025-10-28 | $52.60M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | $12.32M 10-Q · filed 2025-07-29 | $22.91M 10-Q · filed 2025-07-29 | $32.49M derived: sum of 3 quarters · filed 2026-02-24 | $41.58M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | $10.58M 10-Q · filed 2025-04-29 | $20.17M derived: sum of 2 quarters · filed 2026-02-24 | $29.25M derived: sum of 3 quarters · filed 2026-02-24 | $36.95M derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | $9.58M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $18.67M derived: sum of 2 quarters · filed 2026-02-24 | $26.37M derived: sum of 3 quarters · filed 2026-02-24 | $33.41M 10-K · filed 2026-02-24 |
| 2023-09-30 | $9.09M 10-Q · filed 2024-10-29 | $16.79M derived: sum of 2 quarters · filed 2024-10-29 | $23.82M 10-Q · filed 2024-10-29 | $30.53M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | $7.70M 10-Q · filed 2024-07-25 | $14.73M 10-Q · filed 2024-07-25 | $21.45M derived: sum of 3 quarters · filed 2025-02-25 | $28.38M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | $7.04M 10-Q · filed 2024-04-25 | $13.75M derived: sum of 2 quarters · filed 2025-02-25 | $20.68M derived: sum of 3 quarters · filed 2025-02-25 | $25.71M derived: sum of 4 quarters · filed 2025-02-25 |
| 2022-12-31 | $6.71M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $13.65M derived: sum of 2 quarters · filed 2025-02-25 | $18.68M derived: sum of 3 quarters · filed 2025-02-25 | $22.89M 10-K · filed 2025-02-25 |
| 2022-09-30 | $6.94M 10-Q · filed 2023-11-02 | $11.97M derived: sum of 2 quarters · filed 2023-11-02 | $16.18M 10-Q · filed 2023-11-02 | |
| 2022-06-30 | $5.03M 10-Q · filed 2023-08-01 | $9.25M 10-Q · filed 2023-08-01 | ||
| 2021-12-31 | $3.87M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $6.63M derived: sum of 2 quarters · filed 2022-02-24 | $9.10M derived: sum of 3 quarters · filed 2022-02-24 | $9.10M 10-K · filed 2022-02-24 |
| 2021-09-30 | $2.77M 10-Q · filed 2021-11-04 | $5.23M derived: sum of 2 quarters · filed 2021-11-04 | $5.23M 10-Q · filed 2021-11-04 | |
| 2021-06-30 | $2.47M 10-Q · filed 2021-08-05 | $2.47M 10-Q · filed 2021-08-05 | ||
| 2021-03-31 | $0.00 derived: 10-K 12 month − 3 quarters · filed 2022-02-24 |